Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
PLETAL is an oral tablet small-molecule drug approved in 1999 by Otsuka Pharmaceuticals. The mechanism of action and specific indications are not specified in available data. The product is indicated for oral administration in tablet form.
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling potential team downsizing and transition planning opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Worked on PLETAL at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on PLETAL at this lifecycle stage offers experience in defensive marketing, managed decline, and transition planning—valuable skills for portfolio management. Limited linked job openings suggest this is not a growth opportunity and may indicate smaller team size and reduced hiring.